Larazotide Acetate vs KPV
Both are researched for gut inflammation. Larazotide aims to reduce intestinal permeability and reached phase 3 in coeliac disease; KPV is an alpha-MSH fragment studied in rodent colitis models.
Larazotide Acetate
An 8-amino-acid tight-junction regulator designed to reduce intestinal permeability, studied mainly in coeliac disease.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
KPV
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone.
BEST STUDIED FOR
Gut and skin inflammation models
R439View product →
Side by side · to buy
Price, purity and dispatch
| Compare | Larazotide Acetate | KPV10mg |
|---|---|---|
| Price | — | R439 |
| Cost per mg | — | R43.9 / mg |
| Purity (Janoshik) | — | 99.919%HPLC, published |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | View CoA → |
| Literature | — | 4 papers → |
| Research focus | Repair & immune | Gut and skin inflammation models |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Larazotide Acetate | KPV | |
|---|---|---|
| The key difference | Tight-junction regulator (human trials) | Anti-inflammatory tripeptide (preclinical) |
| Class | Repair & immune | Repair & immune |
| Mechanism | Larazotide is proposed to antagonise zonulin-mediated opening of epithelial tight junctions, limiting paracellular passage of gliadin fragments in the gut. | KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone. |
| Status | Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models. | Investigational tripeptide (the C-terminal end of alpha-MSH); not an approved medicine. |
| Reported safety signals | Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme. | No controlled human safety data; findings are from cell and rodent inflammation models. |
| A key study | Reviews tight-junction regulation in coeliac disease with a focus on larazotide. (Ther Adv Gastroenterol 2016, PMID 26770266) | PepT1-mediated uptake of KPV reduced intestinal inflammation and pro-inflammatory signalling in cell and mouse models. (Gastroenterology 2008, PMID 18061177) |
WHEN TO RESEARCH WHICH
Larazotide for barrier research with human data; KPV for preclinical inflammation models. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Larazotide Acetate] The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate — Ther Adv Gastroenterol 2016. PMID 26770266
- [Larazotide Acetate] Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis — Nat Commun 2020. PMID 32332732
- [Larazotide Acetate] Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment — J Control Release 2025. PMID 40915363
- [KPV] PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology 2008. PMID 18061177
- [KPV] Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflamm Bowel Dis 2008. PMID 18092346
- [KPV] Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of anti-inflammatory tripeptide KPV — Cell Mol Gastroenterol Hepatol 2016. PMID 27458604
FREQUENTLY ASKED
What is the difference between Larazotide Acetate and KPV?
Both are researched for gut inflammation. Larazotide aims to reduce intestinal permeability and reached phase 3 in coeliac disease; KPV is an alpha-MSH fragment studied in rodent colitis models.
What is the regulatory status of Larazotide Acetate and KPV?
Larazotide Acetate: Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models. KPV: Investigational tripeptide (the C-terminal end of alpha-MSH); not an approved medicine.
What safety signals have been reported?
Larazotide Acetate: Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme. KPV: No controlled human safety data; findings are from cell and rodent inflammation models.
Which studies is this comparison based on?
For Larazotide Acetate: “The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate” (PMID 26770266); “Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis” (PMID 32332732); “Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment” (PMID 40915363). For KPV: “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation” (PMID 18061177); “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease” (PMID 18092346); “Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of anti-inflammatory tripeptide KPV” (PMID 27458604).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use